Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up

Philip A. Thompson, Alexandre Bazinet, William G. Wierda, Constantine S. Tam, Susan M. O’Brien, Satabdi Saha, Christine B. Peterson, William Plunkett, Michael J. Keating

Blood (2023) 142 (21): 1784–1788.

https://doi.org/10.1182/blood.2023020158

Published: 2023

Includes: Supplemental data

Journal Articles

Outcomes of Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies

Kelly S. Chien, Christine B. Peterson, Elliana Young, Dai Chihara, Elisabet E. Manasanch, Jeremy L. Ramdial, Philip A. Thompson

Blood (2022) 140 (Supplement 1): 10938–10939.

https://doi.org/10.1182/blood-2022-169993

Published: 2022

Journal Articles

Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patients with High Risk CLL Who Have Been on Ibrutinib More Than a Year

Philip A. Thompson, Michael J. Keating, Alessandra Ferrajoli, Nitin Jain, Christine B. Peterson, Naveen Garg, Ana Ayala, Jon A Hernandez, Tapan M. Kadia, Prithviraj Bose, Naveen Pemmaraju, Nicholas Short, William G. Wierda

Blood (2022) 140 (Supplement 1): 238–240.

https://doi.org/10.1182/blood-2022-170030

Published: 2022

Journal Articles

Flow Cytometric Analysis of Microbial Diversity in Patients with Aggressive Lymphoma Disease Undergoing Chemoimmunotherapy

Maren Schmiester, René Maier, René Riedel, Marco Frentsch, Robert R. Jenq, Christine B. Peterson, Liangliang Zhang, Lars Bullinger, Hyun-Dong Chang, Il-Kang Na

Blood (2021) 138 (Supplement 1): 4005.

https://doi.org/10.1182/blood-2021-146429

Published: 2021

Journal Articles

Venetoclax Consolidation in Patients with High-Risk CLL Who Have Been on Ibrutinib More Than a Year Achieves a High Rate of Undetectable Minimal Residual Disease

Philip A. Thompson, Yan Wang, Michael J. Keating, Alessandra Ferrajoli, Nitin Jain, Christine B. Peterson, Naveen Garg, Chongjuan Wei, Ana Ayala, Tapan M. Kadia, Prithviraj Bose, Naveen Pemmaraju, Nicholas J. Short, William G. Wierda

Blood (2021) 138 (Supplement 1): 3723.

https://doi.org/10.1182/blood-2021-149919

Published: 2021

Journal Articles

The Addition of Venetoclax to Ibrutinib Achieves a High Rate of Undetectable Minimal Residual Disease in Patients with High-Risk CLL

Philip A. Thompson, MB, MS, Alessandra Ferrajoli, MD, Nitin Jain, MD, Yan Wang, Christine B Peterson, Naveen Garg, MD, Chongjuan Wei, PhD, Ana Ayala, RN, Tapan M. Kadia, MD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Nicholas J. Short, MD, Michael J. Keating, MBBS, William G. Wierda, MD PhD

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-141716

Published: 2020

Journal Articles

AML Cells Alter Bone Homeostasis By Promoting the Formation of Immature Bone and Resorption of Mature Bone That Supports Leukemia Progression

Anudishi Tyagi, PhD, Bin Yuan, Stanley Ly, Fouad El-Dana, MD, Vinitha Mary Kuruvilla, MSc, Qi Zhang, PhD, Christine B Peterson, Xin Zhou, PhD, Benoit deCrombrugghe, Michael Andreeff, MD PhD, Marina Konopleva, MD PhD, Behrang Amini, MD PhD, Venkata Lokesh Battula, PhD

Blood (2020) 136 (Supplement 1): 27.

https://doi.org/10.1182/blood-2020-142777

Published: 2020

Journal Articles

Hypertension, Cardiovascular and Renal Complications Observed in Patients with Chronic Lymphocytic Leukemia Receiving Long-Term Therapy with Ibrutinib

Jade Jones, MD, Binsah Susan George, MD, Christine B Peterson, Thao-Mi Tran Ha, Jan A. Burger, MD PhD, Nitin Jain, MD, Michael J. Keating, MBBS, William G. Wierda, MD PhD, Jean-Bernard Durand, MD, Alessandra Ferrajoli, MD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-141284

Published: 2020

Journal Articles

Chronic Lymphocytic Leukemia with Deletion 13q: Prognostic Predictors and Outcome after Treatment with Fludarabine, Cyclophosphamide and Rituximab (FCR)

Abdul Rashid Shah, MD, Tariq Muzzafar, MBBS, Romana Asad, MD, Christine B Peterson, Hagop M. Kantarjian, MD, Alessandra Ferrajoli, MD, William G Wierda, MD PhD, Jan A. Burger, MD PhD, Nitin Jain, MD, Gautam Borthakur, MD, Maliha Khan, MD, Abhishek Chilkulwar, MD, Brion Randolph, MD, Lohith Gowda, MD, Michael J Keating

Blood (2017) 130 (Supplement 1): 5337.

https://doi.org/10.1182/blood.V130.Suppl_1.5337.5337

Published: 2017

NARROW

Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up

Outcomes of Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies

Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patients with High Risk CLL Who Have Been on Ibrutinib More Than a Year

Flow Cytometric Analysis of Microbial Diversity in Patients with Aggressive Lymphoma Disease Undergoing Chemoimmunotherapy

Venetoclax Consolidation in Patients with High-Risk CLL Who Have Been on Ibrutinib More Than a Year Achieves a High Rate of Undetectable Minimal Residual Disease

The Addition of Venetoclax to Ibrutinib Achieves a High Rate of Undetectable Minimal Residual Disease in Patients with High-Risk CLL

AML Cells Alter Bone Homeostasis By Promoting the Formation of Immature Bone and Resorption of Mature Bone That Supports Leukemia Progression

Hypertension, Cardiovascular and Renal Complications Observed in Patients with Chronic Lymphocytic Leukemia Receiving Long-Term Therapy with Ibrutinib

Chronic Lymphocytic Leukemia with Deletion 13q: Prognostic Predictors and Outcome after Treatment with Fludarabine, Cyclophosphamide and Rituximab (FCR)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only